- Home
- NKGN vs CLDI Comparison
NKGN vs CLDI Comparison
Compare NKGN & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKGN
- CLDI
- Stock Information
- Founded
- NKGN 2017
- CLDI 2014
- Country
- NKGN United States
- CLDI United States
- Employees
- NKGN N/A
- CLDI N/A
- Industry
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NKGN Health Care
- CLDI Health Care
- Exchange
- NKGN Nasdaq
- CLDI Nasdaq
- Market Cap
- NKGN 37.8M
- CLDI 35.2M
- IPO Year
- NKGN N/A
- CLDI N/A
- Fundamental
- Price
- NKGN $0.57
- CLDI $1.05
- Analyst Decision
- NKGN
- CLDI Strong Buy
- Analyst Count
- NKGN 0
- CLDI 3
- Target Price
- NKGN N/A
- CLDI $16.67
- AVG Volume (30 Days)
- NKGN 10.4M
- CLDI 2.7M
- Earning Date
- NKGN 04-15-2025
- CLDI 03-14-2025
- Dividend Yield
- NKGN N/A
- CLDI N/A
- EPS Growth
- NKGN N/A
- CLDI N/A
- EPS
- NKGN N/A
- CLDI N/A
- Revenue
- NKGN N/A
- CLDI N/A
- Revenue This Year
- NKGN N/A
- CLDI N/A
- Revenue Next Year
- NKGN N/A
- CLDI N/A
- P/E Ratio
- NKGN N/A
- CLDI N/A
- Revenue Growth
- NKGN N/A
- CLDI N/A
- 52 Week Low
- NKGN $0.20
- CLDI $0.58
- 52 Week High
- NKGN $4.06
- CLDI $16.80
- Technical
- Relative Strength Index (RSI)
- NKGN 52.48
- CLDI 45.04
- Support Level
- NKGN $0.40
- CLDI $1.16
- Resistance Level
- NKGN $0.91
- CLDI $1.30
- Average True Range (ATR)
- NKGN 0.13
- CLDI 0.24
- MACD
- NKGN 0.00
- CLDI 0.01
- Stochastic Oscillator
- NKGN 40.78
- CLDI 40.10
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.